Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock Has Consensus Target Price of $48.00

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has earned an average recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $48.00.

Several equities research analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $42.00 price target on shares of Harmony Biosciences in a research report on Thursday, October 1st. WBB Securities raised shares of Harmony Biosciences to a “hold” rating in a report on Friday, October 23rd. Wolfe Research assumed coverage on shares of Harmony Biosciences in a report on Wednesday, August 26th. They issued an “outperform” rating and a $60.00 price objective on the stock. Zacks Research upgraded shares of Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 15th. Finally, Mizuho set a $49.00 target price on shares of Harmony Biosciences in a report on Thursday, October 29th.

Harmony Biosciences Stock Down 5.7%

Harmony Biosciences stock opened at $32.47 on Tuesday. The stock has a market cap of $1.89 billion, a PE ratio of 10.75, a price-to-earnings-growth ratio of 0.28 and a beta of 1.00. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.45 and a current ratio of 3.44. Harmony Biosciences has a one year low of $25.90 and a one year high of $43.49. The stock has a fifty day moving average of $39.49 and a 200 day moving average of $34.71.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Wednesday, November 4th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.28). The firm had revenue of $268.92 million during the quarter, compared to the consensus estimate of $272.05 million. Harmony Biosciences had a net margin of 18.05% and a return on equity of 18.55%. The firm’s revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.08 EPS. As a group, sell-side analysts predict that Harmony Biosciences will post 3.73 EPS for the current year.

Insider Buying and Selling at Harmony Biosciences

In other news, insider Kumar Budur sold 35,852 shares of Harmony Biosciences stock in a transaction on Friday, September 18th. The shares were sold at an average price of $43.05, for a total transaction of $1,543,428.60. Following the transaction, the insider owned 13,115 shares in the company, valued at $564,600.75. This trade represents a 73.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 72,406 shares of company stock worth $3,108,520. Company insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Harmony Biosciences

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Harmony Biosciences during the 2nd quarter worth approximately $258,583,000. Dimensional Fund Advisors LP boosted its position in shares of Harmony Biosciences by 13.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,076,510 shares of the company’s stock worth $58,157,000 after purchasing an additional 245,784 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Harmony Biosciences by 548.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,124,717 shares of the company’s stock worth $44,505,000 after purchasing an additional 951,273 shares during the period. Renaissance Technologies LLC boosted its position in shares of Harmony Biosciences by 0.6% in the first quarter. Renaissance Technologies LLC now owns 1,077,371 shares of the company’s stock worth $30,177,000 after purchasing an additional 6,900 shares during the period. Finally, venBio Partners LLC purchased a new stake in shares of Harmony Biosciences in the second quarter worth $17,192,584. 86.23% of the stock is owned by institutional investors.

More Harmony Biosciences News

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: WAKIX net revenue reached about $269 million in Q3, with 400 net patient additions. Harmony reiterated its 2026 WAKIX revenue outlook of $1.0 billion to $1.04 billion, indicating continued growth expectations. Company Q3 results and outlook
• Positive Sentiment: The company also reported strong multiple-ascending-dose data for its orexin agonist BP-205, supporting its potential profile and offering a possible longer-term growth driver. BP-205 data and Q3 results
• Neutral Sentiment: A CEO transition is beginning. The report does not provide enough detail to assess its potential business impact, but leadership changes may be a point investors monitor. WAKIX outlook and CEO transition
• Negative Sentiment: Q3 adjusted earnings of $0.81 per share missed the $1.09 consensus, while revenue of $268.92 million also came in below estimates of $272.05 million. Higher costs pressured profits; revenue nevertheless grew 12.3% year over year. The earnings miss is the clearest near-term headwind for the stock. Q3 earnings miss and higher costs

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial-stage biopharmaceutical company focused on developing and providing therapies for patients with rare neurological disorders. The company’s activities center on conditions involving sleep-wake regulation and other central nervous system disorders where treatment options may be limited.

Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled treatment that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy.